These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2668784)

  • 21. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of azathioprine treatment in multiple sclerosis.
    Yudkin PL; Ellison GW; Ghezzi A; Goodkin DE; Hughes RA; McPherson K; Mertin J; Milanese C
    Lancet; 1991 Oct; 338(8774):1051-5. PubMed ID: 1681364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Azathioprine for multiple sclerosis.
    Casetta I; Iuliano G; Filippini G
    J Neurol Neurosurg Psychiatry; 2009 Feb; 80(2):131-2; discussion 132. PubMed ID: 19151017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A long-term double-blind controlled study on the effect of azathioprine in the treatment of multiple sclerosis.
    Minderhoud JM; Prange AJ; Luyckx GJ
    Clin Neurol Neurosurg; 1988; 90(1):25-8. PubMed ID: 3359729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic trials in multiple sclerosis: azathioprine.
    Ellison GW; Myers LW; Mickey MR; Frane MV; Tourtellotte WW; Spina CA; Fahey JL
    Ann N Y Acad Sci; 1984; 436():361-5. PubMed ID: 6398018
    [No Abstract]   [Full Text] [Related]  

  • 26. Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report.
    Mertin J; Rudge P; Kremer M; Healey MJ; Knight SC; Compston A; Batchelor JR; Thompson EJ; Halliday AM; Denman M; Medawar PB
    Lancet; 1982 Aug; 2(8294):351-4. PubMed ID: 6124759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
    Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histocompatibility antigens in multiple sclerosis patients participating in a multicentre trial of azathioprine. British & Dutch Multiple Sclerosis Azathioprine Trial Group.
    J Neurol Neurosurg Psychiatry; 1988 Mar; 51(3):412-5. PubMed ID: 3283297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
    Le Page E; Veillard D; Laplaud DA; Hamonic S; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Deburghgraeve V; Coustans M; Edan G; ;
    Lancet; 2015 Sep; 386(9997):974-81. PubMed ID: 26135706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS.
    Weinshenker BG; Issa M; Baskerville J
    Neurology; 1996 Jun; 46(6):1613-9. PubMed ID: 8649559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Azathioprine in treatment of multiple sclerosis. Final results of a 41/2-year controlled study of its effectiveness covering 115 patients.
    Patzold U; Hecker H; Pocklington P
    J Neurol Sci; 1982 Jun; 54(3):377-94. PubMed ID: 7047686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
    Visser LH; Beekman R; Tijssen CC; Uitdehaag BM; Lee ML; Movig KL; Lenderink AW
    Mult Scler; 2004 Feb; 10(1):89-91. PubMed ID: 14760960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double blind study on azathioprine efficacy in multiple sclerosis: final report.
    Milanese C; La Mantia L; Salmaggi A; Eoli M
    J Neurol; 1993 May; 240(5):295-8. PubMed ID: 8326334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Randomized controlled trial of high-dose peroral methylprednisolone in attacks of multiple sclerosis].
    Sellebjerg F; Frederiksen JL; Nielsen PM; Olesen J
    Ugeskr Laeger; 1999 Nov; 161(48):6625-9. PubMed ID: 10643347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disparity between clinical and immune responses in a controlled trial of azathioprine in rheumatoid arthritis.
    GOEBEL KM; Janzen R; Joseph K; Börngen U
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):405-10. PubMed ID: 786666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Results of one-year treatment of multiple sclerosis with azathioprine compared with the therapy using small doses of Encorton].
    Wender M; Tokarz-Kupczyk E; Mularek O; Sniatała-Kamasa M
    Neurol Neurochir Pol; 1991; 25(3):307-13. PubMed ID: 1961376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.